James R. Hitchin

The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells

William J. Harris, Xu Huang, James T. Lynch et al. · Cancer Cell · 2012 · 555 citations

Medicine, Molecular Biology, Oncology +16

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia

Alba Maiqués-Díaz, Gary J. Spencer, James T. Lynch et al. · Cell Reports · 2018 · 222 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib

Dominic I. James, Kate M. Smith, Allan M. Jordan et al. · ACS Chemical Biology · 2016 · 148 citations · Full text

Life Sciences, Biochemistry, Pharmacology +16

Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments

James R. Hitchin, Julian Blagg, Rosemary Burke et al. · MedChemComm · 2013 · 65 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

ERK5 Is a Critical Mediator of Inflammation-Driven Cancer

Katherine G. Finegan, Diana Perez-Madrigal, James R. Hitchin et al. · Cancer Research · 2015 · 61 citations · Full text

Medicine, Cancer Biology, Oncology +17